186 related articles for article (PubMed ID: 35489029)
1. Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.
Mohamoud M; Chen Q; Croteau D; Cheng C; Burkhart K; Volpe DA; Kortepeter C; Demczar D; Stone M
J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):238-246. PubMed ID: 35489029
[TBL] [Abstract][Full Text] [Related]
2. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
[TBL] [Abstract][Full Text] [Related]
3. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
[TBL] [Abstract][Full Text] [Related]
4. Risperidone-to-methylphenidate switch reaction in children: three cases.
Sabuncuoglu O
J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
[TBL] [Abstract][Full Text] [Related]
5. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
6. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Moran LV; Ongur D; Hsu J; Castro VM; Perlis RH; Schneeweiss S
N Engl J Med; 2019 Mar; 380(12):1128-1138. PubMed ID: 30893533
[TBL] [Abstract][Full Text] [Related]
7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
8. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
9. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
10. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder.
Bali V; Kamble PS; Aparasu RR
J Manag Care Spec Pharm; 2015 Jun; 21(6):486-98. PubMed ID: 26011550
[TBL] [Abstract][Full Text] [Related]
11. Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder.
Scholle O; Banaschewski T; Enders D; Garbe E; Riedel O
J Child Adolesc Psychopharmacol; 2018; 28(6):415-422. PubMed ID: 29768038
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
13. ADHD Masquerading as Cautopyreiophagia Exacerbated by Risperidone and Improved With Methylphenidate in a Preschooler.
Naguy A
Prim Care Companion CNS Disord; 2021 Jul; 23(4):. PubMed ID: 34228405
[No Abstract] [Full Text] [Related]
14. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
[TBL] [Abstract][Full Text] [Related]
15. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
Correia Filho AG; Bodanese R; Silva TL; Alvares JP; Aman M; Rohde LA
J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):748-55. PubMed ID: 16034276
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
[TBL] [Abstract][Full Text] [Related]
17. Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Stämpfli D; Weiler S; Burden AM
Eur Child Adolesc Psychiatry; 2021 Jul; 30(7):1047-1058. PubMed ID: 32621088
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
19. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.
Penzner JB; Dudas M; Saito E; Olshanskiy V; Parikh UH; Kapoor S; Chekuri R; Gadaleta D; Avedon J; Sheridan EM; Randell J; Malhotra AK; Kane JM; Correll CU
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):563-73. PubMed ID: 19877981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
